Sitagliptin May Cut Mortality in T2DM Patients With COVID-19
WEDNESDAY, Oct. 14, 2020 -- Sitagliptin treatment added to standard care is associated with reduced mortality and improved clinical outcomes for patients with type 2 diabetes hospitalized with COVID-19, according to a study published online Sept. 29...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: COVID-19 | Diabetes | Diabetes Type 2 | Endocrinology | Januvia | Pharmaceuticals | Study